What is survodutide? What it does, benefits and what the evidence shows

Survodutide is an investigational injectable peptide from Boehringer Ingelheim that activates two receptors at once, glucagon and GLP-1. It is not an approved drug: we found no approved product, and DailyMed had no survodutide label when we searched it on September 28, 2026. It is being studied for obesity and for fatty liver disease (MASH and MASLD), and its first Phase 3 obesity results have now been published in the New England Journal of Medicine, so it is further along than most of what gets sold under a "research peptide" label.

What survodutide is and how it works

Survodutide (development code BI 456906) is a glucagon receptor and GLP-1 receptor dual agonist. The GLP-1 half is the same target that semaglutide hits: it reduces appetite. The glucagon half is the twist. Glucagon signaling is thought to raise energy expenditure and act on the liver, which is why survodutide has been pushed toward fatty liver disease as well as weight loss. In preclinical work, survodutide lowered body weight by decreasing energy intake and increasing energy expenditure, and mouse experiments in a 2026 paper were consistent with its appetite-suppressing effect depending on the GLP-1 receptor rather than the glucagon one (Molecular Metabolism, 2026). That is animal mechanism work, not proof of what happens in people.

Boehringer Ingelheim develops it under a license from Zealand Pharma, and Boehringer is solely responsible for development and commercialization worldwide (Boehringer Ingelheim, October 8, 2024 press release). The same release lists the regulatory designations it holds for the liver indication: FDA Fast Track (May 2021), FDA Breakthrough Therapy (September 2024), and entry into the European Medicines Agency's PRIME scheme (November 2023). Those designations speed up development and review. They are not approvals.

Two other investigational obesity drugs covered in our guides, retatrutide and mazdutide, also work on more than one hormone receptor, so survodutide is often shopped alongside them. We found no head-to-head trial comparing survodutide with either, so comparisons between the drugs are guesses across different trials.

What people use it for

The type 2 diabetes row rests on a post hoc look at two Phase 2 trials, one of them in 413 adults with type 2 diabetes on metformin. Survodutide was associated with improved beta-cell function and insulin sensitivity markers versus placebo, and the authors note the durability of that effect after stopping is unknown (Diabetes, Obesity & Metabolism, 2026). Post hoc means the analysis was chosen after the data were in, so this is a lead, not a result. The dedicated Phase 3 diabetes-and-obesity trial is covered below.

What the research actually shows

Weight loss

SYNCHRONIZE-1 is the pivotal obesity trial. It randomized 725 adults with obesity, or with overweight plus at least one obesity-related complication but no diabetes, to one of two survodutide doses or placebo, all alongside lifestyle counseling. The two co-primary endpoints were percent change in body weight and the share of people losing at least 5% by the end of the treatment period, about a year and a half in. Using the treatment-regimen estimand, which counts people who stopped the drug early or used prohibited weight-loss medicines, average weight change was -12.2% and -13.0% on the two doses against -5.4% on placebo. Weight loss of at least 5% happened in 72.6% and 71.9% of people on survodutide versus 46.3% on placebo (Phase 3 SYNCHRONIZE-1 trial, NEJM, 2026). Boehringer Ingelheim funded the trial.

Two things are worth holding onto. First, placebo plus counseling still lost 5.4%, so the drug-attributable gap is roughly 7 to 8 percentage points on this analysis. Second, the paper's primary analysis is the stricter of the two ways of counting. Company announcements often headline the efficacy estimand, which assumes everyone stayed on treatment and produces bigger numbers, so figures you see in news coverage may be higher than the ones quoted here.

The earlier Phase 2 obesity trial enrolled 387 adults and showed dose-dependent weight loss, from -6.2% on the lowest dose to -14.9% on the highest, versus -2.8% on placebo. Only 60.4% of participants completed the treatment period, a reminder that tolerability shaped how well these results held up (Lancet Diabetes & Endocrinology, 2024).

Fatty liver disease (MASLD and MASH)

The liver is where survodutide is most different from its competitors. In SYNCHRONIZE-MASLD, 216 adults with obesity and at-risk fatty liver disease were randomized two-to-one to survodutide or placebo. Liver fat fell by at least 30% in 84.2% of survodutide-treated people versus 24.3% on placebo (efficacy estimand); under the stricter treatment-regimen estimand it was 68.5% versus 28.6%. Mean body weight change was -12.2% versus -1.0% (efficacy estimand) or -8.7% versus -1.4% (treatment-regimen). The authors list two limitations: a short trial and limited geography, with participants recruited only in the United States and Spain (Nature Medicine, 2026). Liver fat measured by MRI is a marker, not a clinical outcome like cirrhosis or death.

For actual liver disease, the best evidence is still Phase 2. In 293 adults with biopsy-confirmed MASH and fibrosis, 43% to 62% across the three survodutide doses had improvement in MASH without worsening of fibrosis, versus 14% on placebo. Improvement in fibrosis itself was much less striking: 34% to 36% versus 22% (NEJM, 2024). A later analysis of that trial estimated that weight loss explained roughly two-thirds of the MASH-resolution effect but a smaller share of the fibrosis effect, which suggests some direct liver action beyond weight loss (Hepatology, 2026). It was a post hoc analysis, so it generates a hypothesis rather than settling one. The two Phase 3 liver trials, LIVERAGE and LIVERAGE-Cirrhosis, are still recruiting according to ClinicalTrials.gov, with the registry listing primary completion of the larger trial around the end of 2031 (LIVERAGE; LIVERAGE-Cirrhosis).

What hasn't reported yet

ClinicalTrials.gov lists the Phase 3 diabetes-and-obesity trial (SYNCHRONIZE-2) and a cardiovascular safety trial of more than 5,000 people (SYNCHRONIZE-CVOT) as completed, most recently updated in August and September 2026. Neither has posted results on the registry, and we found no published paper for either. We also could not confirm any regulatory filing. So the honest status is: two of the pivotal readouts are in, others are not, and nothing has been approved.

Side effects and risks

Stomach symptoms dominate. In SYNCHRONIZE-1, gastrointestinal adverse events, typically mild to moderate, occurred in 80.9% and 89.7% of people on the two doses versus 47.9% on placebo, and no deaths were reported (NEJM, 2026). In the Phase 2 MASH trial, nausea (66% vs 23% on placebo), diarrhea (49% vs 23%) and vomiting (41% vs 4%) were the events that stood out; serious adverse events were similar, 8% on survodutide and 7% on placebo (NEJM, 2024). In the SYNCHRONIZE-MASLD trial, the gastrointestinal events mostly occurred while the dose was being stepped up.

What is unknown is bigger than what is known. The abstracts we could open do not report long-term safety beyond the trial periods, and the cardiovascular safety trial has not reported. Trial participants were screened, monitored and given gradual dose increases under protocol; none of that describes what happens when someone buys a vial with no matching clinical oversight. The grey-market-specific risks are the ones our data can speak to: whether the vial contains the compound, how pure it is, whether the quantity matches the label, and, for an injectable, whether it is free of endotoxin (see endotoxin in research peptides).

What the lab tests show

Here is the thin part. As of September 29, 2026, our database holds exactly one survodutide vial, from a lab report dated May 2025. It measured 99.60% pure and about 6% over its labeled amount. That isn't a failure under our failure definition (empty, under 95% pure, more than 20% under label or more than 50% over), but one vial from one report says almost nothing about what other vials, other batches or other vendors look like. Please don't read it as a quality signal for the compound or for any seller.

Because we don't have enough lab data on survodutide to rank vendors for it, the table below shows the highest-ranked vendors across all compounds right now. A vendor's overall record is a signal, not a guarantee for a compound they have never had tested:

Buying smarter

Start by checking whether the vendor has any survodutide result at all on the survodutide results page, and look at how many reports sit behind any score on /vendors; our methodology page explains what a ranked vendor needs. With a compound this thinly covered, a vendor's posted COA carries more of the weight than usual, which is exactly when to verify it: how to read a peptide COA and fake peptide COAs cover the red flags.

Buyers who have their own vial tested are the reason a database like this exists. How to get a peptide tested walks through identity, purity and quantity testing, and underdosed peptides explains why quantity matters as much as purity. If your report comes back bad, stop using that batch, tell anyone who bought from the same run, take the report to the vendor, and submit it to VendorVerify. If you have a survodutide result of any kind, good or bad, submitting it is the fastest way to give the next buyer more than a single data point. For the background on the market, see what are grey market peptides.

If you're comparing survodutide against approved incretin drugs, semaglutide and tirzepatide are the ones with full label data and long-term safety records; survodutide has neither yet.

Database figures are from VendorVerify as of September 29, 2026. This isn't medical advice. Survodutide is an investigational drug and is sold outside clinical trials for research use only.